Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.com 

AI-enabled healthcare and genomics could deliver the next photonics-like returns, as AI transforms the sector and improves success rates just as it did in tech. The market is getting ready to price these names as future winners, and those that succeed will be real winners. Beaten-down stocks such as AbCellera, Tempus AI and Twist Bioscience, plus the ARK Genomic Revolution ETF, are looking at billion-dollar markets. x.com 

AI drug-discovery picks and shovels such as Ginkgo Bioworks, 10x Genomics, Twist Bioscience and Grail are priced on a fantasy, and secondary offerings are coming. The bet that AI will solve cancers and rare diseases within months ignores how drug discovery, regulation and trial enrollment actually work. Unlike the semiconductor comparison, these businesses have not inflected, mostly burn cash, trade at 20-30x sales and need equity to fund themselves. Buyers here become their liquidity. x.com  … Show more

Biotech is the next AI trade, as AI turns drug discovery from a 10-year guessing game into a data problem while investors still treat the sector like a casino. Tempus AI uses a large clinical dataset for AI diagnostics; Recursion maps over a trillion cells with Genentech and Sanofi as partners; CRISPR Therapeutics has catalysts before end-2026; Absci designs antibodies with generative AI and starts Phase 2; Schrödinger sells physics-plus-AI design software and posted a surprise profit. x.com  … Show more

Recursion Pharmaceuticals could see huge catalysts from positive phase I and II news due in the second half of this year. Its AI drug-discovery platform has five clinical trials in progress, and big pharma and biopharma are spending billions on AI-driven platforms. Market research firms project 38-45% annual growth for AI genomics through the early 2030s. The stock found support around $3 and has some momentum. x.com 

Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.com 

Tempus AI is being repriced because its acquisition of Personalis benefits directly from positive Moderna news, while short covering is still underway. Short interest is about 30 million shares, over eight days of normal 3-5 million share volume, and the three-day surge absorbed under a third of it. A small market cap makes the stock easy to push higher, and bullish divergences on the three-day and weekly charts usually last weeks to months. Resistance sits at 74-76, 80 and 84-86. x.com  x.com  … Show more

These 12 stocks offer exposure to AI, automation, health care, consumer growth and nuclear demand. AMD makes AI chips; Oracle builds AI cloud; Vertex has multiple drug opportunities. Arista supplies data-center switches, KLA inspection tools and Cadence chip-design tools. Palantir sells AI platforms; Symbotic automates warehouses; Alphabet spans search, cloud and AI. Celsius has US consumer momentum, AppLovin runs high-margin mobile ads, and Cameco mines uranium and co-owns Westinghouse. x.com  … Show more

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Tempus AI is becoming a bigger health-tech player as pharma deals add a new services revenue stream beyond selling tests. BTIG's Mark Massaro raised his target to $80 from $70 with a Buy rating, mainly because Tempus will be the sequencing provider for Moderna and Merck's cancer vaccine program. The Personalis deal and MRD momentum add to a strengthening long-term AI and precision-oncology story, despite near-term volatility. x.com